RDEA3170 and Febuxostat Drug Interaction Study
Study Details
Study Description
Brief Summary
This study will evaluate the potential pharmacokinetic (PK) and pharmacodynamic (PD) interaction between the XO inhibitor febuxostat and the investigational URAT1 inhibitor RDEA3170 and provide information for potential future clinical studies using this combination. Combination treatment using 2 drugs with different mechanisms of action may achieve improved response and may allow the use of lower doses, resulting in fewer side effects than the use of either drug alone.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Febuxostat Days 1-7: febuxostat 40 mg qd. Days 8-14: RDEA3170 10 mg or placebo qd in combination with febuxostat 40 mg qd. Days 15-21: RDEA3170 10 mg or placebo qd. |
Drug: RDEA3170 10 mg
RDEA3170 10 mg once daily (qd)
Drug: Febuxostat 40 mg
Febuxostat 40 mg qd
Drug: placebo
placebo qd
|
| Experimental: RDEA3170 Days 1-7: RDEA3170 10 mg or placebo qd. Days 8-14: RDEA3170 10 mg or placebo qd in combination with febuxostat 40 mg qd. Days 15-21: febuxostat 40 mg qd. |
Drug: RDEA3170 10 mg
RDEA3170 10 mg once daily (qd)
Drug: Febuxostat 40 mg
Febuxostat 40 mg qd
Drug: placebo
placebo qd
|
Outcome Measures
Primary Outcome Measures
- PK profile of RDEA3170 from plasma and urine and febuxostat from plasma [Days -1 (urine only), 7, 14, 21 and Days 8, 15, 22 (plasma only)]
Profile from plasma and urine in terms of AUC, Tmax, Cmax, t1/2, Ae, and CLr AUC: area under the concentration-time curve; Tmax: time to maximum plasma concentration; Cmax: maximum plasma drug concentration; t1/2: apparent terminal half-life; Ae: amount excreted of unchanged drug into urine; CLr: renal clearance
Secondary Outcome Measures
- PD profile of RDEA3170 and febuxostat alone and in combination [Days -1, 7, 14, 21 and Days 8, 15, 22 (serum only)]
Profile from serum and urine in terms of sUA concentration, renal clearance of uric acid, urine uric acid excretion amounts, and fractional excretion of uric acid. sUA: serum urate
- Incidence of Adverse Events and Changes in Laboratory, Electrocardiogram, and Vital Signs Parameters [8 weeks]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
body weight ≥ 50 kg (110 lbs.) and a body mass index ≥ 18 and ≤ 40 kg/m2.
-
no clinically relevant abnormalities in vital signs, ECG, physical examination or safety laboratory values, per the Investigator's judgment.
-
a screening serum urate level ≥ 4.5 mg/dL.
Exclusion Criteria:
-
history or suspicion of kidney stones.
-
history of cardiac abnormalities as assessed during screening, including abnormal and clinically relevant electrocardiogram changes and/or family history of sudden death in otherwise healthy individual between the ages of 1 and 30 years.
-
undergone major surgery within 3 months prior to Day 1.
-
donated blood or experienced significant blood loss (> 450 mL) within 12 weeks prior to Day 1 or gave a plasma donation within 4 weeks prior to the Screening Period.
-
inadequate venous access or unsuitable veins for repeated venipuncture.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Kalamazoo | Michigan | United States | 49007 |
Sponsors and Collaborators
- Ardea Biosciences, Inc.
Investigators
- Study Director: S. Baumgartner, Ardea Biosciences, Inc.
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- RDEA3170-105